You are here: Industry Insights > balstilimab

News List

Agenus BLA for Balstilimab as Treatment for Cervical Cancer Granted Priority Review by U.S. FDA americanpharmaceuticalreview
June 18, 2021
Agenus Inc., an immuno-oncology company with an extensive pipeline of agents including checkpoint antibodies, cell therapies, adjuvants, and vaccines that activate immune response to cancers and infections announced that the U.S. FDA accepted Agenus’ ...
Agenus Submits Balstilimab Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer americanpharmaceuticalreview
April 20, 2021
Agenus Inc., an immuno-oncology company with an extensive pipeline of agents which includes checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, announced the submission of a ...
Immunotherapies to treat cervical cancer show promise in Phase II trials europeanpharmaceuticalreview
October 16, 2020
Novel programmed cell death protein 1 immunotherapies for cervical cancer have demonstrated success in two Phase II clinical trials in the US.
Agenus Receives Fast Track Designation for Cervical Cancer Treatment americanpharmaceuticalreview
March 17, 2020
Agenus announced the U.S. Food and Drug Administration (FDA) has granted Agenus Fast Track designation for investigation of balstilimab [PD-1] in combination ...
Agenus Commences Phase 1 Trial with AGEN1223 americanpharmaceuticalreview
January 09, 2020
Agenus announced the dosing of the first patient with AGEN1223. AGEN1223 is a novel bi-specific antibody discovered by Agenus and designed to deplete regulatory T cells in the tumor microenvironment.